Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

Key Points

• To assess the impact of resmetirom on health-related quality of life in patients with early MASH and MASH cirrhosis.
• Analyzed health-related quality of life scores before and after resmetirom treatment.
• Included patients across the spectrum of MAFLD from early MASH to MASH cirrhosis.
• Evaluated disease-specific outcomes.
• Patients experienced significant improvements in certain disease-specific HRQL scores after treatment with resmetirom.